

Tacrolimus Granules (PROGRAF) for Oral Suspension

Criteria for Use

July 2026

VA Pharmacy Benefits Management Services and National Formulary Committee

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

Inclusion Criteria

All the following must be selected to meet criteria.

- ☐ The medication is safe and clinically appropriate as determined by a VA/VA Community care prescriber using shared decision making
- ☐ Difficulty swallowing oral capsule¹

Footnotes

1. Utilization of a commercially available granular formulation minimizes risk of aerosolization and reduces staff exposure to a hazardous drug.

Original: July 2026

Contact: N. Antonovich, PharmD, BCPS, National Program Manager, VA Pharmacy Benefits Management Services – Formulary Management (12PBM)
